If patent reform legislation is going to pass in this Congress, consensus will be needed over any reform of the inter partes review process. Since Kyle Bass and Erich Spangenberg started challenging the validity of a series of life sciences patents earlier this year, IPR reform has become the big reform issue for the pharma and biotech communities.

Want to read more?

Register to access two of our subscriber-only articles per month

Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts

Already registered? Log in

What our customers are saying

Excellent articles and focus on best practices.

Ruud Peters
Advisor
Philips Intellectual Property & Standards

Benefits

Subscribe to receive access to the full range of premium business intelligence, insights and analysis, as well as our IP directories, guides and daily news.

Why subscribe?